MARKET

BHVN

BHVN

Biohaven
NYSE
38.72
-0.89
-2.25%
Closed 17:36 04/24 EDT
OPEN
40.19
PREV CLOSE
39.61
HIGH
40.62
LOW
38.38
VOLUME
971.89K
TURNOVER
0
52 WEEK HIGH
62.21
52 WEEK LOW
12.35
MARKET CAP
3.38B
P/E (TTM)
-6.7542
1D
5D
1M
3M
1Y
5Y
BIOHAVEN LTD <BHVN.N>: UBS RAISES TARGET PRICE TO $60 FROM $59
Reuters · 1d ago
Weekly Report: what happened at BHVN last week (0415-0419)?
Weekly Report · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Surgical, Crypto stocks, Jabil
Wall Street's main indexes eyed a flat open on Friday. Netflix drops after forecasting current-quarter revenue below estimates. Intuitive Surgical rises as demand for surgical robots boosts Q1 results. Crypto stocks climb as bitcoin climbs ahead of 'halving' of the currency.
Reuters · 5d ago
BIOHAVEN LTD: OFFERING 5.6 MLN OF COMMON SHARES IN THIS OFFERING AT PRICE PER COMMON SHARE OF $41.00
Reuters · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 6d ago
BUZZ-Biohaven dips after $230 mln equity raise
Biohaven's BHVN.N shares down 2.6% at $42.90 before the bell after follow-on priced. Biotech firm announces $230 mln equity raise. Firm's stock has roughly tripled over the past 12 months. Company is developing an experimental inflammatory disease drug.
Reuters · 6d ago
BIOHAVEN LTD - PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5,609,757 OF ITS COMMON SHARES AT A PRICE TO PUBLIC OF $41.00 PER SHARE
Reuters · 6d ago
More
About BHVN
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Webull offers Biohaven Ltd stock information, including NYSE: BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.